Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 ...

Prothena (PRTA – Research Report) received a Hold rating and price target from Oppenheimer analyst Jay Olson yesterday. The company’s shares closed last Friday at $6.58. Confi ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Prothena (PRTA – Research Report) and Bristol-Myers Squibb (BMY – Research Report). Confident ...

Fintel reports that on May 27, 2025, Oppenheimer downgraded their outlook for Prothena (NasdaqGS:PRTA) from Outperform to Perform. Analyst Price Forecast Suggests 1,057.57% Upside As of May 7, 2025, ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end ...

History has repeated itself for Prothena Corp. plc, which has reported a second phase III miss for birtamimab in the treatment of light chain amyloidosis. Announcing the trial failure, the ...